Stockholders Approve 6 Million Share Increase for Equity Incentive Plan, Potential Dilution of 63%

summarizeSummary

IMMUNIC, INC. stockholders approved an amendment to increase the shares authorized for its equity incentive plan by 6,000,000, bringing the total to 8,644,887 shares, which could result in significant future dilution.

check_boxKey Events · Financing and Capital Events · IMUX

• Equity Incentive Plan Share Increase

  Stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing the number of shares authorized for issuance by 6,000,000 to a total of 8,644,887 shares. Based on 13,621,483 outstanding shares, if all authorized shares under the plan were issued, potential dilution would be approximately 63.46%.

• Director Elections

  Mr. Michael Bonney, Mr. Thorvald Nagel, and Dr. Richard Rudick were elected as Class III Directors to serve until the 2029 annual meeting.

• Auditor Ratification

  The appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified by stockholders.

auto_awesomeAnalysis · IMUX · Life Sciences

Stockholders approved a significant increase in shares authorized for the company's equity incentive plan. The additional 6,000,000 shares bring the total authorized for the plan to 8,644,887. If all these shares were issued, it would represent a substantial dilution of approximately 63% to existing shareholders. This authorization provides the company with considerable flexibility for future equity-based compensation, but also creates a large overhang of potential dilution.